Navigation Links
New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
Date:10/24/2007

advanced cancer this quarter and plan to evaluate RDEA119 for inflammatory diseases next year."

About RDEA119 and Ardea's MEK Inhibitor Program

Ardea Biosciences has a broad-based R&D program focused on the design and development of small-molecule inhibitors of mitogen-activated ERK kinase, or MEK, for the treatment of cancer and inflammatory diseases. Since defects in the RAS/RAF/MEK/ERK signaling pathway are closely associated with the development of human tumors, such as melanoma, colon, lung and thyroid cancers, inhibiting MEK signaling has promise in the treatment of many types of cancer. MEK inhibitors may also play an important role in the potential treatment of inflammatory diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and psoriasis, due to their ability to down-regulate inflammatory cytokines, such as TNF alpha.

RDEA119, Ardea's lead compound from this program, is a potent, non-ATP competitive, highly- selective inhibitor of MEK. Ardea plans to initiate a Phase 1 clinical trial evaluating RDEA119 in advanced cancer patients in the fourth quarter of 2007. Preclinical data suggest that RDEA119 may have favorable pharmaceutical properties, including the potential for convenient oral dosing and limited retention in the brain, which, in turn, may result in a reduced risk of CNS side effects. Beyond RDEA119, the Company is evaluating a broad range of MEK inhibitors from several distinct chemical classes and plans to bring forward one of these compounds into a first-in-human study in the fourth quarter of this year.

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV,
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Blurb shows that print still captures imaginations
2. Kauffman study shows consistent entrepreneurial growth
3. Directory shows high-tech growth spurt in Dane Co.
4. Stem cell therapy shows visionary promise
5. TDS restates years of revenues, shows slight profit drop
6. As BIO shows mass of competition, hunt for partners is on
7. UW shows why avian flu hasnt spread among humans yet
8. NameProtect study shows 92% of top brands losing out on search engines
9. Stem cell breakthrough by UW shows why federal research should be broadened
10. Student survey shows surging demand for wireless access
11. Wisconsins tech employment shows increase, HR firm reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Inc. (Nasdaq: OSTE ), a leader in ... healing, announced today that it has submitted a ... Drug Administration (FDA) to obtain marketing clearance for ... repair or replace the dura mater (the outermost ... procedures. This filing is based, in part, ...
(Date:12/17/2009)... /PRNewswire-Asia/ -- Using a novel stem cell based,technology ... eliminate a glioma -- brain cancer -- of ... in Beijing. The treatment shows that the activated,immune ... well as cancer daughter,cells. The amazing outcome of ... Cellonis that the future vaccination therapies may be,targeted ...
(Date:12/17/2009)... rise the U.S. in November, even as the overall unemployment rate ... in the pharmaceutical industry. , ... (Vocus) December 17, ... job losses - which is to say, there were no ... area was related to the Pfizer acquisition of Wyeth. Meanwhile, healthcare ...
(Date:12/17/2009)... the Daveys, the GLOBALS, ,and PM360 Pharma Choice Awards Programs. ... ... -- Chicago-based full-service healthcare communications agency Goble & Associates, Inc. ... honoring exceptional creative and interactive work. , , ,THE RX ... Awards of Excellence for the following creative work: Hospira LifeShield ...
Breaking Biology Technology:Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix 2Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix 3For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4The MedZilla Report for November 2009 - Healthcare Employment Up, And No Major Bad News for Pharma, Either 2The MedZilla Report for November 2009 - Healthcare Employment Up, And No Major Bad News for Pharma, Either 3Goble & Associates Creative Work Awarded at Advertising Industry Competitions 2Goble & Associates Creative Work Awarded at Advertising Industry Competitions 3Goble & Associates Creative Work Awarded at Advertising Industry Competitions 4
... 7 - Decision Taken to Advance ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused ... Exchange: BINV), announce today that they have,successfully completed ... first Phase I trial of TB-402, which is ...
... Globally, approximately 418 billion,people are currently infected with ... hepatitis in the 21st century cannot be,understated or ... by Kalorama Information. Paradoxically, despite the obvious ... to contain hepatitis. Yet the incidence and,prevalence of ...
... N.J., Sept. 6 Pharmasset, Inc.,(Nasdaq: VRUS ... four scientific,presentations related to R7128 for the treatment ... at the 14th International Symposium on Hepatitis C,Virus ... 2007 in Glasgow,Scotland. R7128, a prodrug of PSI-6130, ...
Other Biology Technology:ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:12/16/2009)... Athletes, superstitions and rituals can help them get psyched ... anti-inflammatory drugs (NSAIDs), which many athletes gobble down before ... than good. , "These agents are treatments for the ... Stuart Warden, whose research at Indiana University focuses on ... athlete to exercise or train at a certain level, ...
(Date:12/16/2009)... 15, 2009 Signal Hill, CA Tom Bowman, ... and president of Bowman Global Change, has developed a ... fourth Intergovernmental Panel on Climate Change (IPCC) report for ... the authentic scientific information they need to make informed ... created the new format as a means to clearly ...
(Date:12/16/2009)... Dec. 1 GestureTek Inc. today ... 3.0 - a turnkey, portable, plug and ... exhibits, entertainment and touring promotions. GestureTek is ... patents in camera-enabled gesture recognition technology for ... Guaranteed for quality, the CUBE has TUV, ...
Breaking Biology News(10 mins):NSAIDs: Take 'em early and often when competing? Think again 2Bowman creates graphic translation of climate change data 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 1Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 2Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 3Americans United for Lifes Statement on Finance Committee Vote 59407 1XLHealth Applauds Quality Focused Reforms in Senate Finance Committee Legislation 59404 1XLHealth Applauds Quality Focused Reforms in Senate Finance Committee Legislation 59404 2
... genetic information concerning the long-disputed origin of the ... University of La Laguna, and the International Potato ... remnants of the earliest known landraces of the ... They report their findings in the May-June 2007 ...
... Keeping at arm's length won't protect you from catching ... University of Technology which reveals airborne viruses can spread ... QUT's International Laboratory for Air Quality and Health, said ... humans only travel a metre in the air. ...
... creatures that live in the deepest parts of the Pacific ... the unlikeliest of habitats ?the carcass of a dead whale. ... sea anemone isn't so unusual. But finding one that calls ... apart. , Since the scientists who initially found these ...
Other Biology News:Spud origin controversy solved 2Spreading viruses as we breathe 2From the deep -- Researchers find new species of sea anemone 2From the deep -- Researchers find new species of sea anemone 3
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
... consists of ten double-stranded RNAs, 10, 20, ... and 1,000 base pairs. The dsRNA Marker ... sizes of double-stranded RNAs. A twenty bp ... is adjusted to approximately 25 ng/µl in ...
... off-white solid. A nucleoside antibiotic that ... formation of N-glycosidic protein-carbohydrate linkages. Active ... bacteria, yeasts, fungi, and viruses. Inhibits ... on human T-lymphoblastoid cells. Also inhibits ...
... a group of enzymes involved in matrix ... metalloproteinase family ten exist in soluble form ... MT1-MMP, MT2-MMP, MT3-MMP also known as MMP14, ... domain anchoring them to the cell surface. ...
Biology Products: